Luye Pharma Group Full Year 2023 Earnings: EPS Misses Expectations

Luye Pharma Group (HKG:2186) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥6.14b (up 2.7% from FY 2022).
• Net income: CN¥532.6m (down 12% from FY 2022).
• Profit margin: 8.7% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.14 (down from CN¥0.17 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Luye Pharma Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 7.8% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Luye Pharma Group's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.